Key Record Dates Identifier: NCT03625323
Brief Title: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)

First Submitted : July 16, 2018
First Submitted that Met QC Criteria : August 9, 2018
First Posted : August 10, 2018

Last Update Submitted that Met QC Criteria : April 7, 2021
Last Update Posted : April 9, 2021